These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15148584)

  • 1. [Secondary prevention of cardiovascular diseases].
    Schneider CA; Erdmann E
    Internist (Berl); 2004 Jun; 45 Suppl 1():S23-30. PubMed ID: 15148584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of myocardial infarcts. Facts and myths].
    Stiefelhagen P
    MMW Fortschr Med; 2006 May; 148(18):4-6, 8. PubMed ID: 16736675
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary prevention of myocardial infarction: putting the evidence to use.
    Herzog E; Javed F
    Arch Intern Med; 2010 Aug; 170(15):1381-2. PubMed ID: 20696965
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary prevention after acute myocardial infarction and coronary revascularisation: focus on Angiotensin converting enzyme inhibitors.
    Kaski JC; Fernandez-Berges D
    Cardiovasc Drugs Ther; 2008 Jun; 22(3):185-91. PubMed ID: 18317916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of secondary prevention medical therapies on outcomes of patients suffering from Myocardial Infarction with NonObstructive Coronary Artery disease (MINOCA): A meta-analysis.
    De Filippo O; Russo C; Manai R; Borzillo I; Savoca F; Gallone G; Bruno F; Ahmad M; De Ferrari GM; D'Ascenzo F
    Int J Cardiol; 2022 Dec; 368():1-9. PubMed ID: 35987312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).
    Fonarow GC; Gawlinski A; Moughrabi S; Tillisch JH
    Am J Cardiol; 2001 Apr; 87(7):819-22. PubMed ID: 11274933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commentary on NICE guidance for secondary prevention for patients following a myocardial infarction.
    Skinner JS; Minhas R
    Heart; 2007 Jul; 93(7):864-6. PubMed ID: 17569812
    [No Abstract]   [Full Text] [Related]  

  • 9. Statin and beta-blocker therapy and the initial presentation of coronary heart disease.
    Go AS; Iribarren C; Chandra M; Lathon PV; Fortmann SP; Quertermous T; Hlatky MA;
    Ann Intern Med; 2006 Feb; 144(4):229-38. PubMed ID: 16490908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Stable coronary artery disease--invasive treatment does not replace secondary prevention].
    Kettunen R; Lepojärvi M; Laine M
    Duodecim; 2012; 128(7):720-7. PubMed ID: 22612022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease.
    Ladapo JA; Hoffmann U; Lee KL; Coles A; Huang M; Mark DB; Dolor RJ; Pelberg RA; Budoff M; Sigurdsson G; Severance HW; Douglas PS
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27733347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prevention for patients following a myocardial infarction: summary of NICE guidance.
    Skinner JS; Cooper A; Feder GS;
    Heart; 2007 Jul; 93(7):862-4. PubMed ID: 17569811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Secondary prevention after cardiac infarct; therapeutic efficiency--cost-benefit ratio].
    Kreuzer J; Kübler W
    Internist (Berl); 2001 May; 42(5):713-9. PubMed ID: 11400578
    [No Abstract]   [Full Text] [Related]  

  • 14. Do All Patients Need β-Blockers After a Heart Attack?
    Abbasi J
    JAMA; 2018 Mar; 319(9):853-855. PubMed ID: 29450492
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pharmacotherapy after cardiac infarction].
    Darius H; Meyer J
    Internist (Berl); 2001 May; 42(5):699-712. PubMed ID: 11400577
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacological prevention of coronary relapses in Italian clinical practice: a literature review].
    Pedrinelli R; Ciccone M; Novo S; Catapano AL
    G Ital Cardiol (Rome); 2012 Nov; 13(11):734-40. PubMed ID: 23096582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Factors influencing secondary prevention of atherothrombotic disease in the private outpatient cardiology setting: results of the Prisma survey].
    Cambou JP; Ferrieres J; Grenier O; Boka G; Cantet C; Leizorovicz A
    Ann Cardiol Angeiol (Paris); 2003 Feb; 52(1):20-9. PubMed ID: 12710291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary prevention after myocardial infarction].
    Pflumm JE; Pomykaj T; Heintzen MP
    Internist (Berl); 2008 Sep; 49(9):1052-60. PubMed ID: 18651118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Secondary prevention of coronary heart disease. How effective are modern therapy methods?].
    Kolenda KD
    Dtsch Med Wochenschr; 2003 Sep; 128(36):1849-53. PubMed ID: 12964107
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.
    Høgh AL
    Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.